Compare PLBY & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLBY | RLYB |
|---|---|---|
| Founded | 1953 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.0M | 89.2M |
| IPO Year | 2020 | 2021 |
| Metric | PLBY | RLYB |
|---|---|---|
| Price | $1.13 | $17.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 406.9K | 8.0K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | N/A | ★ 6.16 |
| Revenue | ★ $120,928,000.00 | $858,000.00 |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | ★ N/A | $2.80 |
| Revenue Growth | 4.13 | ★ 43.00 |
| 52 Week Low | $1.08 | $0.48 |
| 52 Week High | $2.75 | $17.57 |
| Indicator | PLBY | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 46.40 |
| Support Level | $1.09 | $16.51 |
| Resistance Level | $1.30 | $17.32 |
| Average True Range (ATR) | 0.04 | 0.42 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 4.17 | 1.32 |
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.